96 related articles for article (PubMed ID: 23900680)
1. A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma.
Waldron NN; Barsky SH; Dougherty PR; Vallera DA
Target Oncol; 2014 Sep; 9(3):239-49. PubMed ID: 23900680
[TBL] [Abstract][Full Text] [Related]
2. An EpCAM/CD3 bispecific antibody efficiently eliminates hepatocellular carcinoma cells with limited galectin-1 expression.
Zhang P; Shi B; Gao H; Jiang H; Kong J; Yan J; Pan X; Li K; Zhang P; Yao M; Yang S; Gu J; Wang H; Li Z
Cancer Immunol Immunother; 2014 Feb; 63(2):121-32. PubMed ID: 24177984
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of catumaxomab in tumor spheroid killing is mediated by its trifunctional mode of action.
Hirschhaeuser F; Walenta S; Mueller-Klieser W
Cancer Immunol Immunother; 2010 Nov; 59(11):1675-84. PubMed ID: 20652245
[TBL] [Abstract][Full Text] [Related]
4. Eradication of Heterogeneous Tumors by T Cells Targeted with Combination Bispecific Chemically Self-assembled Nanorings.
Petersburg J; Vallera DA; Wagner CR
Mol Cancer Ther; 2023 Mar; 22(3):371-380. PubMed ID: 36548194
[TBL] [Abstract][Full Text] [Related]
5. Adoptive therapy of head and neck squamous cell carcinoma with antibody coated immune cells: a pilot clinical trial.
Riechelmann H; Wiesneth M; Schauwecker P; Reinhardt P; Gronau S; Schmitt A; Schroen C; Atz J; Schmitt M
Cancer Immunol Immunother; 2007 Sep; 56(9):1397-406. PubMed ID: 17273869
[TBL] [Abstract][Full Text] [Related]
6. Elevated tissue factor procoagulant activity in CD133-positive cancer cells.
Milsom C; Anderson GM; Weitz JI; Rak J
J Thromb Haemost; 2007 Dec; 5(12):2550-2. PubMed ID: 17883595
[No Abstract] [Full Text] [Related]
7. Catumaxomab: clinical development and future directions.
Linke R; Klein A; Seimetz D
MAbs; 2010; 2(2):129-36. PubMed ID: 20190561
[TBL] [Abstract][Full Text] [Related]
8. Antigen forks: bispecific reagents that inhibit cell growth by binding selected pairs of tumor antigens.
Ring DB; Hsieh-Ma ST; Shi T; Reeder J
Cancer Immunol Immunother; 1994 Jul; 39(1):41-8. PubMed ID: 8044825
[TBL] [Abstract][Full Text] [Related]
9. DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 3, X-linked is an immunogenic target of cancer stem cells.
Koshio J; Kagamu H; Nozaki K; Saida Y; Tanaka T; Shoji S; Igarashi N; Miura S; Okajima M; Watanabe S; Yoshizawa H; Narita I
Cancer Immunol Immunother; 2013 Oct; 62(10):1619-28. PubMed ID: 23974721
[TBL] [Abstract][Full Text] [Related]
10. Immunoregulatory Potential of Exosomes Derived from Cancer Stem Cells.
Clayton SM; Archard JA; Wagner J; Farwell DG; Bewley AF; Beliveau A; Birkeland A; Rao S; Abouyared M; Belafsky PC; Anderson JD
Stem Cells Dev; 2020 Mar; 29(6):327-335. PubMed ID: 31856674
[TBL] [Abstract][Full Text] [Related]
11. A novel antibody-drug conjugate targeting SAIL for the treatment of hematologic malignancies.
Kim SY; Theunissen JW; Balibalos J; Liao-Chan S; Babcock MC; Wong T; Cairns B; Gonzalez D; van der Horst EH; Perez M; Levashova Z; Chinn L; D'Alessio JA; Flory M; Bermudez A; Jackson DY; Ha E; Monteon J; Bruhns MF; Chen G; Migone TS
Blood Cancer J; 2015 May; 5(5):e316. PubMed ID: 26024286
[TBL] [Abstract][Full Text] [Related]
12. Tregs activated by bispecific antibodies: Killers or suppressors?
Koristka S; Cartellieri M; Arndt C; Feldmann A; Seliger B; Ehninger G; Bachmann MP
Oncoimmunology; 2015 Mar; 4(3):e994441. PubMed ID: 25949920
[TBL] [Abstract][Full Text] [Related]
13. Generation of a Novel SORT1×HER2 Bispecific Antibody-Drug Conjugate Targeting HER2-Low-Expression Tumor.
Zhuang W; Zhang W; Wang L; Xie L; Feng J; Zhang B; Hu Y
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003245
[TBL] [Abstract][Full Text] [Related]
14. Identification and characterization of a subpopulation of CD133
Gao J; Yang T; Wang X; Zhang Y; Wang J; Zhang B; Tang D; Liu Y; Gao T; Lin Q; Tang J; Cai J
Cancer Cell Int; 2021 Mar; 21(1):157. PubMed ID: 33685462
[TBL] [Abstract][Full Text] [Related]
15. An evolving paradigm of cancer stem cell hierarchies: therapeutic implications.
Cole AJ; Fayomi AP; Anyaeche VI; Bai S; Buckanovich RJ
Theranostics; 2020; 10(7):3083-3098. PubMed ID: 32194856
[TBL] [Abstract][Full Text] [Related]
16. The role of CD133 in cancer: a concise review.
Glumac PM; LeBeau AM
Clin Transl Med; 2018 Jul; 7(1):18. PubMed ID: 29984391
[TBL] [Abstract][Full Text] [Related]
17. A high-content screen for small-molecule regulators of epithelial cell-adhesion molecule (EpCAM) cleavage yields a robust inhibitor.
Tretter JY; Schorpp K; Luxenburger E; Trambauer J; Steiner H; Hadian K; Gires O; Niessing D
J Biol Chem; 2018 Jun; 293(23):8994-9005. PubMed ID: 29700109
[TBL] [Abstract][Full Text] [Related]
18. Up-modulation of PLC-β2 reduces the number and malignancy of triple-negative breast tumor cells with a CD133
Brugnoli F; Grassilli S; Lanuti P; Marchisio M; Al-Qassab Y; Vezzali F; Capitani S; Bertagnolo V
BMC Cancer; 2017 Sep; 17(1):617. PubMed ID: 28870198
[TBL] [Abstract][Full Text] [Related]
19. Effects of a Phosphoinositide-3-Kinase Inhibitor on Anaplastic Thyroid Cancer Stem Cells.
Bozorg-Ghalati F; Hedayati M; Dianatpour M; Azizi F; Mosaffa N; Mehrabani D
Asian Pac J Cancer Prev; 2017 Aug; 18(8):2287-2291. PubMed ID: 28843268
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic antibodies against cancer stem cells: a promising approach.
Sneha S; Nagare RP; Priya SK; Sidhanth C; Pors K; Ganesan TS
Cancer Immunol Immunother; 2017 Nov; 66(11):1383-1398. PubMed ID: 28840297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
